Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

OncoTargets and Therapy
Panagiotis MalandrakisEvangelos Terpos

Abstract

Multiple myeloma (MM) is one the most common hematological malignancies, and despite the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and anti-CD38 monoclonal antibodies, the need for novel agents is prominent. Selinexor is a first-in-class, oral, selective inhibitor of exportin-1 (XPO1), a vital protein for the exportation of more than 200 tumor suppressor proteins from the nucleus. Both in solid tumors and hematologic malignancies, selinexor-mediated inhibition of nucleus export seems to effectively lead to cancer cell death. Selinexor in combination with dexamethasone (Sd) received an accelerated FDA approval on July 2019 for heavily pretreated patients with relapsed/refractory MM (RRMM) based on the promising results of the Phase II STORM trial. The preliminary results of the randomized Phase III BOSTON trial have shown a 47% increase in progression-free survival among PI-sensitive, RRMM patients who received selinexor with bortezomib-dexamethasone compared with bortezomib-dexamethasone alone. Several different selinexor-containing triplet regimens are currently being tested in the RRMM setting in an umbrella trial, and the preliminary results seem promising. Furthermore, the ...Continue Reading

References

Jul 16, 2014·Clinical Lymphoma, Myeloma & Leukemia·Kevin B KnopfRaymond L Comenzo
Aug 27, 2015·The New England Journal of Medicine·Henk M LokhorstPaul G Richardson
Mar 2, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albiruni R Abdul RazakAmit Mahipal
Mar 16, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosEvangelos Terpos
Mar 19, 2016·Journal of Cellular Physiology·Cheryl Taylor-KashtonSabine Mai
Jul 3, 2017·Translational Oncology·Barbara MuzAbdel Kareem Azab
Jan 14, 2018·Blood Cancer Journal·Evangelos TerposMeletios A Dimopoulos
Jan 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dan T VoglA Keith Stewart
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Adam D Cohen
Dec 21, 2018·Aging·Maria GavriatopoulouMeletios Athanasios Dimopoulos
Jan 11, 2019·Leukemia & Lymphoma·Maria GavriatopoulouMeletios Athanasios Dimopoulos
Feb 28, 2019·Expert Review of Anticancer Therapy·Maria GavriatopoulouEvangelos Terpos
Apr 17, 2019·Proceedings of the National Academy of Sciences of the United States of America·Jie XuSai-Juan Chen
May 3, 2019·The New England Journal of Medicine·Noopur RajeJames N Kochenderfer
May 28, 2019·British Journal of Haematology·Andrzej J JakubowiakJeffrey A Zonder
Aug 21, 2019·Drugs·Yahiya Y Syed
Aug 23, 2019·The New England Journal of Medicine·Ajai ChariSundar Jagannath
Sep 24, 2019·Clinical Lymphoma, Myeloma & Leukemia·Alessandro AllegraCaterina Musolino
Oct 22, 2019·OncoTargets and Therapy·Reinhard DeppingFriederike Katharina Kosyna
Nov 27, 2019·Cancer Treatment Reviews·Ioannis Ntanasis-StathopoulosMeletios A Dimopoulos
Jan 8, 2020·Expert Opinion on Drug Safety·Taiga Nishihori, Rachid Baz
Jan 17, 2020·Expert Opinion on Biological Therapy·Ioannis Ntanasis-StathopoulosEvangelos Terpos
Jan 21, 2020·Expert Opinion on Pharmacotherapy·Klaus PodarSundar Jagannath
Feb 23, 2020·British Journal of Haematology·Rajshekhar Chakraborty, Fabio Efficace
Mar 27, 2020·American Journal of Hematology·S Vincent Rajkumar
Apr 5, 2020·Clinical Lymphoma, Myeloma & Leukemia·Joseph MikhaelSuzanne Lentzch
May 8, 2020·Clinical Lymphoma, Myeloma & Leukemia·Evangelos TerposUNKNOWN International Myeloma Society

❮ Previous
Next ❯

Citations

Nov 12, 2021·Expert Opinion on Pharmacotherapy·Maria GavriatopoulouMeletios Athanasios Dimopoulos

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Clinical Trials Mentioned

NCT01607892
NCT02343042
NCT02199665
NCT03589222
NCT02186834
NCT02336815
NCT03110562

Software Mentioned

SELIBORDARA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved